Le Lézard
Classified in: Health, Science and technology
Subject: FDA

US FDA grants VICO Therapeutics Orphan-Drug Designation for VO659, an Investigational Therapy for Spinocerebellar Ataxia

LEIDEN, The Netherlands, June 29, 2021 /PRNewswire/ -- VICO Therapeutics, a Leiden, the Netherlands, based biotech company focusing on the development of RNA modulating therapies for rare neurological disorders, today announced that the Office of Orphan Products Development (OOPD) of the U.S. Food and Drug Administration (FDA) has granted orphan-drug designation for VO659, VICO's investigational antisense oligonucleotide (AON) therapy for the treatment of spinocerebellar ataxia (SCA). In February, VICO already received orphan drug designation for VO659 in SCA from the European Commission.

VICO Therapeutics Logo

Rupert Sandbrink MD PhD., Chief Medical Officer at VICO, stated: 

"Spinocerebellar ataxia belongs to the group of polyglutamine disorders which are debilitating and progressive diseases, leading to significant impairment of mobility and multiple other daily activities of patients suffering from these conditions. Currently, no disease modifying treatments are available for these patients. Our investigational RNA modulating therapy is designed to lower the mutant protein levels causing these neurodegenerative diseases."

"We're excited to obtain orphan-drug designation from also the FDA, following the EC grant earlier this year. This deeply underserved patient population deserves new therapies, and we look forward to advancing VO659, our therapy that holds great potential for addressing their unmet needs. It also recognizes the potential of our AON approach. This is yet another important step forward as we prepare for our first in human trials, expected to start in 2022."

FDA's Office of Orphan Products Development grants Orphan Drug Designation to drugs and biologics that are defined as those intended for the safe and effective treatment, diagnosis or prevention of rare diseases/disorders that affect fewer than 200,000 people in the U.S. The designation allows VICO to qualify for a number of incentives, including seven years of market exclusivity upon regulatory approval; exemption from FDA application fees for spinocerebellar ataxia; and tax credits for qualified clinical trials.



VICO Therapeutics B.V.
Gertjan Bartlema, Chief Executive Officer
T: +31 (0)71 203 68 31
E: Gertjan.bartlema@vicotx.com 

LifeSpring Life Sciences Communication, Amsterdam, the Netherlands
Leon Melens
T: +31 6 538 16 427
E: lmelens@lifespring.nl

About SCA

Spinocerebellar ataxia (SCA) is a group of rare, progressive hereditary genetic disorders that affects the cerebellum, brain stem and spinal cord. More than 30 types of SCAs have been identified to date (SCA1?SCA36), and the most common SCAs (types 1, 2, 3, 6 and 7) are caused by translated CAG trinucleotide repeat expansions that encode elongated polyglutamine (polyQ) stretches in the respective disease proteins. Presence of the elongated polyQ stretch confers pathogenic properties to the resulting protein through a dominant gain-of-function mechanism, resulting in degeneration of specific neuronal subpopulations that differ between the different SCA types. For SCA1 and SCA3 disease manifestation includes ataxia of gait, stance, and limbs, dysarthria, and oculomotor abnormalities. To date, there are no disease-modifying therapies.

About VO659

VICO's lead antisense oligonucleotide product, VO659 is designed to suppress mutant proteins and slow or halt disease progression. A major strength of VICO's approach is the broad applicability to different polyQ diseases and the preferential reduction of mutant relative to normal polyQ proteins.

About VICO Therapeutics

VICO Therapeutics is a Leiden, the Netherlands, based private biotech company focusing on the development of RNA modulating therapies for rare severe neurological disorders. VICO's antisense oligonucleotide platform (AON) is focusing on different forms of spinocerebellar ataxia (SCA) and Huntington Disease (HD). Its early discovery RNA editing platform is directed towards RETT syndrome.

SOURCE Vico Therapeutics

These press releases may also interest you

at 11:30
Wipro Limited , a leading global information technology, consulting and business process services company has signed a multi-year global strategic IT and digital deal with London - headquartered National Grid, a leading multinational electric and gas...

at 11:29
Baylin Technologies Inc. (the "Company") announces that it has completed the second and final tranche (the "Final Tranche") of its previously announced private placement (the "Offering") of a minimum of 11,765,000 common shares of the Company...

at 11:29
TopCashback.com (TopCashback), the USA's most generous cash back website, is launching a three-day event beginning October 25 to mark its 10th birthday with major saving opportunities for members....

at 11:27
The role of product marketing is on the rise. It's no longer seen as a nice-to-have, it's a company commodity for forward-thinking, fast-growing, market-dominating organizations worldwide. Companies recruiting product marketers has increased 5X in...

at 11:26
A new market study published by Global Industry Analysts Inc., (GIA) the premier market research company, today released its report titled "Nano Healthcare Technology for Medical Equipment - Global Market Trajectory & Analytics". The report presents...

at 11:25
Information Services Group (ISG) , a leading global technology research and advisory firm, has launched a research study examining service providers supporting enterprise adoption and management of Salesforce solutions. The study results will be...

News published on 29 june 2021 at 03:00 and distributed by: